Early-Stage Breast Carcinoma Clinical Trial
— PICTURE XSOfficial title:
PICTURE Breast XS: Patient Information Combined for Local Therapy oUtcome Assessment in bREast Cancer - Cross-sectional
Verified date | October 2016 |
Source | University College, London |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This project which is fully funded by the European Union FP7 Program is designed to pull together all the information we obtain from scans and x-rays to design a personalised 3-D digital model of each patient, their anatomy and disease. We can then use this as follows: as (i) an aid to surgical planning to enable objective clinical decision making (ii) a decision support tool to communicate the available treatment options to the patient and facilitate shared decision making and provision of personalised care and (iii) to enable standardised objective evaluation of the aesthetic outcome of the treatment procedures. This study aims to demonstrate the ability of the Virtual Physiological Human concept to empower breast cancer patients and assess the impact on their care and quality of life.
Status | Completed |
Enrollment | 222 |
Est. completion date | December 2016 |
Est. primary completion date | February 2016 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Women who have undergone breast conserving surgery for early breast cancer more than one year ago. - Written informed consent obtained. Exclusion Criteria: - Unable to provide written informed consent. - Younger than 18 years. - Benign breast disease. - Women who have had a mastectomy. |
Country | Name | City | State |
---|---|---|---|
Netherlands | Leiden University Medical Center (LUMC) | Leiden | |
Portugal | Champalimaud Cancer Center | Lisbon | |
United Kingdom | Royal Free Hospital | London |
Lead Sponsor | Collaborator |
---|---|
University College, London | European Union |
Netherlands, Portugal, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluate the factors that determine aesthetic outcome after treatment for early breast cancer | The primary aim of this study is to evaluate the factors that determine aesthetic outcome after treatment for early breast cancer, based on a consensual classification obtained with a consensus panel. The information thus obtained will be integrated into the demonstrator (a personalised digital representation of the patient). | Single assessment on one day, beyond one year from date of primary surgery. | |
Secondary | Comparison of the characteristics of this patient group with the group used to make the demonstrator in PICTURE L (composite outcome). | Comparison of the characteristics of the primary tumour in this patient group with the group used to make the demonstrator. The characteristics include: primary tumour side, quadrant, size, and hormone receptor status. | Single assessment on one day, beyond one year from date of primary surgery. | |
Secondary | Comparison of the characteristics of this patient group with the group used to make the demonstrator in PICTURE L (composite outcome). | Comparison of the characteristics of treatment received in this patient group with the group used to make the demonstrator. The characteristics include: details of surgery, chemotherapy, radiotherapy and adjuvant hormonal therapy. | Single assessment on one day, beyond one year from date of primary surgery. | |
Secondary | Comparison of the characteristics of this patient group with the group used to make the demonstrator in PICTURE L (composite outcome). | Comparison of the characteristics assessed by questionnaire of this patient group with the group used to make the demonstrator. The characteristics include: measures assessed by the questionnaires (EQ-5D-5L, QLQ-C30 & BR23, and BREAST-Q). | Single assessment on one day, beyond one year from date of primary surgery. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04290897 -
Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors
|
Phase 2 | |
Active, not recruiting |
NCT02592083 -
Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors
|
Phase 2 | |
Active, not recruiting |
NCT02568839 -
Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT02481128 -
Surgical Trial to Evaluate the Impact of a Lymphoscintigraphy Prior to Sentinel Node Biopsy in Early Breast Cancer
|
N/A | |
Active, not recruiting |
NCT03077841 -
Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT02511301 -
Circadian Thermal Sensing to Detect Breast Disease
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02474641 -
Hypofractionation With Simultaneous Integrated Boost vs. Standard Fractionation in Early Breast Cancer
|
N/A | |
Withdrawn |
NCT04560439 -
Diabetes Prevention Program (METFIT) in Reducing Insulin Resistance in Stage I-III Breast Cancer Survivors
|
N/A | |
Completed |
NCT02129686 -
A Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients
|
N/A | |
Completed |
NCT02806817 -
ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism
|
Early Phase 1 | |
Recruiting |
NCT02947425 -
TARGeted Intraoperative radioTherapy (TARGIT) Registry Database
|
||
Active, not recruiting |
NCT02603679 -
Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases
|
Phase 2 | |
Active, not recruiting |
NCT03025139 -
Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness)
|
N/A | |
Completed |
NCT04081389 -
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
|
Phase 1 | |
Completed |
NCT02441946 -
A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer
|
Phase 2 | |
Completed |
NCT04294225 -
Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer
|
Phase 2 |